Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS

Journal of Internal Medicine

Volumn 258, Issue 1, 2005, Pages 21-27

  Norata, G D ^a,b   Garlaschelli, K ^b   Ongari, M ^b   Raselli, S ^b   Grigore, L ^b   Benvenuto, F ^b   Maggi, F M ^a   Catapano, Alberto L ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b Center for the Study of Atherosclerosis   (Italy)

Author keywords

Cyclo oxygenase 2; Gene expression; Inflammation; Interleukin 6; Lipopolysaccharide; Toll like receptors

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR 4;

ADULT; ARTICLE; CD40 GENE; COX2 GENE; FEMALE; GENE; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; HUMAN; IL6 GENE; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY CELL; INTIMA; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MCP1 GENE; MONOCYTE; PRIORITY JOURNAL; PTX3 GENE; RLP13A GENE; THICKNESS; TLR4 GENE;

ALLELES; ANTIGENS, CD40; C-REACTIVE PROTEIN; CAROTID ARTERY, COMMON; CAROTID STENOSIS; CHEMOKINE CCL2; CYCLOOXYGENASE 2; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MIDDLE AGED; MONOCYTES; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RECEPTORS, CELL SURFACE; SERUM AMYLOID P-COMPONENT; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS;

EID: 21344468658     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01509.x     Document Type: Article

References (33)

1. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 1876-90.
2. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
3. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
4. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105: 1158-61.
5. Vink A, Schoneveld AH, van der Meer JJ et al. In vivo evidence for a role of toll-like receptor 4 in the development of intimai lesions. Circulation 2002; 106: 1985-90.
6. Bobryshev YV, Ikezawa T, Watanabe T. Formation of Birbeck granule-like structures in vascular dendritic cells in human atherosclerotic aorta. Lag-antibody to epidermal Langerhans cells recognizes cells in the aortic wall. Atherosclerosis 1997; 133: 193-202.
7. Pasterkamp G, Van Keulen JK, De Kleijn DP. Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur J Clin Invest 2004; 34: 328-34.
8. Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science 1998; 282: 2085-8.
9. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164: 558-61.
10. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001; 167: 2887-94.
11. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003; 278: 1561-8,
12. Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A. The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med 1998; 187: 2097-101.
13. Arbour NC, Lorenz E, Schutte BC et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-91.
14. Kiechl S, Lorenz E, Reindl M et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185-92.
15. Ameziane N, Beillat T, Verpillat P et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003; 23: e61-4.
16. Morange PE, Tiret L, Saut N et al. TLR4/Asp299Gly, CD14/C260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study. Eur J Hum Genet 2004; 12: 1041-9.
17. Zee RY, Hegener HH, Gould J, Ridker PM. Toll-like receptor 4 Asp299Gly gene polymorphism and risk of atherothrombosis, Stroke 2005; 36: 154-7.
18. Boekholdt SM, Agema WR, Peters RJ et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003; 107: 2416-21.
19. Netea MG, Hijmans A, van Wissen S et al. Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia. Eur J Clin Invest 2004; 34: 94-9.
20. Beutler B, Beutler E. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 1978-80: author reply 1978-80.
21. Yang IA, Holloway JW, Ye S. TLR4 Asp299Gly polymorphism is not associated with coronary artery stenosis. Atherosclerosis 2003; 170: 187-90.
22. Edfeldt K, Bennet AM, Eriksson P et al. Association of hyporesponsive toll-like receptor 4 variants with risk of myocardial infarction. Eur Heart J 2004; 25: 1447-53.
23. Norata GD, Callegari E, Inoue H, Catapano AL. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. Arterioscler Thromb Vasc Biol 2004; 24: 871-77.
24. Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S, Witztum JL. Toll-like receptor 4-dependent and independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol 2005; 25: 1-7.
25. Shi Q, Wang J, Wang XL, VandeBerg JL. Comparative analysis of vascular endothelial cell activation by TNF-alpha and LPS in humans and baboons. Cell Biochem Biophys 2004; 40: 289-304.
26. Kadl A, Huber J, Gruber F, Bochkov VN, Binder BR, Leitinger N. Analysis of inflammatory gene induction by oxidized phospholipids in vivo by quantitative real-time RT-PCR in comparison with effects of LPS. Vascul Pharmacol 2002; 38: 219-27.
27. 7 Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782-7.
28. Shi W, Wang X, Tangchitpiyanond K, Wong J, Shi Y, Lusis AJ. Atherosclerosis in C3H/HeJ mice reconstituted with apolipoprotein E-null bone marrow. Arterioscler Thromb Vasc Biol 2002; 22: 650-5.
29. Kathiresan S, Newton-Cheh C, Gerszten RE. On the interpretation of genetic association studies. Eur Heart J 2004; 25: 1378-81.
30. Wright SD, Burton C, Hernandez M et al. Infectious agents are not necessary for murine atherogenesis. J Exp Med 2000; 191: 1437-42.
31. Michelsen KS, Wong MH, Shah PK et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A 2004; 101: 10679-84.
32. Erridge C, Stewart J, Poxton IR. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J Exp Med 2003; 197: 1787-91.
33. Prebeck S, Kirschning C, Durr S et al. Predominant role of toll-like receptor 2 versus 4 in Chlamydia pneumoniae-induced activation of dendritic cells. J Immunol 2001; 167: 3316-23.